Interesting to read the response of clinicians regarding the recent FDA review:-
https://endpts.com/clinicians-say-benefits-of-car-t-continue-to-outweigh-risk-of-t-cell-malignancies/
In it states the following:-
The agency has not responded to requests for comment on how many CAR-positive T-cell malignancies were detected and the severity of the cases. Bishop noted that CAR-positive cases do not necessarily mean the patient’s cancer was caused by CAR-T treatment, and more information will be necessary to determine whether patients were predisposed to T-cell lymphomas.
The fact that T-cell lymphomas is specifically mentioned, bodes extremely well for PTX-100.... the fact that it is a targeted therapy and not a Car-T therapy. Surely, the FDA will be more receptive to our upcoming submission.
- Forums
- ASX - By Stock
- PTX Media related
Interesting to read the response of clinicians regarding the...
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.3¢ |
Change
-0.002(4.44%) |
Mkt cap ! $36.23M |
Open | High | Low | Value | Volume |
4.4¢ | 4.4¢ | 4.3¢ | $5.2K | 120.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 320988 | 4.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.3¢ | 51021 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 320988 | 0.042 |
5 | 499890 | 0.041 |
7 | 643294 | 0.040 |
7 | 597589 | 0.039 |
8 | 757382 | 0.038 |
Price($) | Vol. | No. |
---|---|---|
0.043 | 50562 | 2 |
0.044 | 197855 | 2 |
0.045 | 424491 | 6 |
0.047 | 613389 | 3 |
0.050 | 66739 | 3 |
Last trade - 12.57pm 25/07/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |